A5022596189- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Myasthenia Gravis and Thymoma
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Immune Cell Function and Interaction
- Antifungal resistance and susceptibility
- Cell Adhesion Molecules Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Chemokine receptors and signaling
- Virus-based gene therapy research
- T-cell and Retrovirus Studies
- Cytokine Signaling Pathways and Interactions
- Atherosclerosis and Cardiovascular Diseases
- Polyomavirus and related diseases
- Advanced Biosensing Techniques and Applications
- Genomics and Rare Diseases
- 14-3-3 protein interactions
- Parkinson's Disease and Spinal Disorders
- Neurogenesis and neuroplasticity mechanisms
- Artificial Immune Systems Applications
Medical Products Agency
2021-2024
European Medicines Agency
2021-2024
Istituto Superiore di Sanità
2023
Weatherford College
2023
Agencia Española de Medicamentos y Productos Sanitarios
2023
AstraZeneca (Sweden)
2010
Karolinska Institutet
1995-2009
Karolinska University Hospital
1997-2009
University of Ottawa
2002-2003
Ottawa Hospital
2002
Myelin-directed autoimmunity is considered to play a key role in the pathogenesis of multiple sclerosis (MS). Increased production both pro- and anti-inflammatory cytokines common finding MS. Interleukin-17 (IL-17) recently described cytokine produced humans almost exclusively by activated memory T cells, which can induce proinflammatory chemokines from parenchymal cells macrophages. In situ hybridisation with synthetic oligonucleotide probes was adopted detect enumerate IL-17 mRNA...
Background and Purpose —Ischemic brain injury secondary to an arterial occlusion is characterized by acute local inflammation. Blood polymorphonuclear leukocytes (PMNL), primarily neutrophils, adhere endothelial cells rapidly invade the injured after occlusion. This neutrophilic invasion might correlate with production of certain chemoattractants blood mononuclear (MNC). We evaluated mRNA expression CXC chemokine interleukin (IL)-8, CC chemokines monocyte chemoattractant protein-1,...
Ischemic stroke is associated with altered systemic immune responses both early after the onset and in recovery phase. Interleukin (IL)‐10, a Th2 related cytokine, has multiple effects on different cell types, including T B lymphocytes, monocytes, neutrophis mast cells. IL‐4 another cytokine that inhibits synthesis of pro‐inflammatory cytokines by Th1 clones. We used enzyme‐linked immunospot assays to detect enumerate blood mononuclear cells (MNC) secreting IL‐10 spontaneously as well...
Abstract IL-15, produced by monocytes and epithelial cells, is a novel cytokine with actions similar to IL-2. IL-15 induces T cell proliferation, B maturation natural killer (NK) cytotoxicity, chemoattractant for cells. We investigated the expression of mRNA in blood cerebrospinal fluid (CSF) mononuclear cells (MNC) MS, an inflammatory disease central nervous system where cytokines are involved. MS patients had higher numbers mRNA-expressing MNC than aseptic meningo-encephalitis (AM) healthy...
The interactions of CD28-B7 and CD40-CD40 ligand (CD40L) pathways in T cell co-stimulation autoimmune disease are incompletely understood. We sought to address this issue by investigation the genesis acetylcholine receptor (AChR)-induced antibody-mediated experimental myasthenia gravis (EAMG) CD28- CD40L-deficient mice (CD28− / − , CD40L− ). Compared wild-type mice, CD28− became less susceptible, were completely resistant EAMG induction. Analysis helper functions, reflected cytokine...
SUMMARY MS is an inflammatory, presumably autoimmune, disease mediated by the activation of T cells, B cells and monocytes (MO). Inflammation thought to occur early during relapsing-remitting phase (RRMS), whereas in later phases such as secondary progressive (SPMS), inflammation tends diminish. Our objective was compare types amounts proinflammatory regulatory cytokines produced MO from relapsing–remitting patients with or without treatment IFN-β (RRMS+ therapy, RRMS− therapy),...
Interferon-β-1b (IFN-β-1b) is an immunomodulatory therapy of multiple sclerosis (MS), reducing the numbers and severity exacerbations total lesion load measured by magnetic resonance imaging brain. The benefits IFN-β-1b could be hampered development neutralising antibodies against compound. Our results confirmed earlier studies, showing that 42% MS patients treated with for more than 3 months had developed antibodies. occurrence binding anti-IFN-β-1b antibodies, presently not believed to...
Objectives - Multiple sclerosis (MS) is characterized by high levels of circulating mononuclear cells (MNC) that respond to myelin proteins like basic protein (MBP) in vitro expressing mRNA both pro-inflammatory cytokines, e.g. interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and lymphotoxin (LT) may make MS worse, anti-inflammatory cytokines IL-4, IL-10 transforming growth factor-β (TGF-β) act beneficially. Substances down-regulate such as TNF-α or promote TGF-β can be anticipated...
Inflammatory cell infiltration within the central nervous system (CNS) and upregulation of both pro‐ anti‐inflammatory cytokines are characteristic for multiple sclerosis (MS). Treatment with interferon‐β1b (IFN‐β1b) reduces number severity MS relapses. To examine whether treatment IFN‐β1b affects levels cytokine mRNA expressing blood mononuclear cells (MNC) we employed in‐sit hybridization synthetic oligonucleotide probes to detect enumerate IFN‐γ, TNF‐α, IL‐10, TGF‐β perforin in patients...
To characterize the involvement of costimulatory pathways in pathogenesis myasthenia gravis (MG), a multiparameter flow cytometry assay was adopted to enumerate blood mononuclear cells (MNC) expressing CD28, CD80, CD86, CD40, and CD40L molecules patients with MG healthy subjects. Patients had lower percentages CD8+CD28+ cells, augmented CD4+CD80+, CD4+CD86+, CD8+CD80+, CD8+CD86+, CD14+CD80+, CD14+CD86+ similar levels CD40 B CD80 CD86 compared controls. early onset (<40 years) CD3+CD86+,...
Enhanced expression of pro- and anti-inflammatory cytokines is a common finding in MS, but attempts to correlate cytokine with disease activity have produced conflicting results. In this paper, gadolinium-(Gd-)enhancing lesions on brain MRI were used as markers for active inflammation patients MS not treated any immunomodulatory drugs. parallel, situ hybridization was detect blood cerebrospinal fluid (CSF) mononuclear cells (MNC) expressing mRNA. An association observed between numbers...
Since the implementation of EU Orphan Regulation in 2000, Committee for Medicinal Products at European Medicines Agency has been evaluating benefits proposed orphan medicines vs. satisfactory treatment methods. This type evaluation is foreseen as designation criterion called “significant benefit.” In this article, based on 20 years experience, we provide a commentary explaining what considered method context and purpose assessment significant benefit. We discuss challenges posed by...
Acute unilateral monosymptomatic optic neuritis (ON) is a common first manifestation of MS if associated with multiple MS-like lesions on brain MRI and oligoclonal IgG bands (OB) in the CSF, whereas ON patients lacking these laboratory abnormalities are considered to have good prognosis regarding future development. Several cytokines involved immune regulation upregulated blood even more noticeable CSF MS. To study possible relation between cytokine profiles presence versus absence OB, we...